Abstract
There are no established therapeutic regimens for hepatitis C virus (HCV) patients who relapse following treatment with interferon α-2b and ribavirin or those who break through while on interferon α-2b and ribavirin. We therefore evaluated various combination therapies in HCV patients who relapsed or experienced a viral breakthrough. Patients (n = 124) were randomized to 48 weeks of treatment with once-weekly subcutaneous injections of 180 μg pegylated (peg-) interferon α-2a plus oral ribavirin (800–1000 mg/day), mycophenolate mofetil (2 g/day), amantadine (200 mg/day), or ribavirin and amantadine and followed for an additional 24 weeks. The sustained virologic response was higher in patients administered peginterferon α-2a plus ribavirin (38%) or ribavirin and amantadine (45%) than in those administered peginterferon α-2a plus mycophenolate mofetil (17%) or amantadine (10%). As in previous studies, patients with genotype non-1 and those with lower viral loads had better responses than those with genotype 1 and high viral loads, though the differences did not reach significance. The four treatment regimens had similar safety profiles, except that patients receiving ribavirin had greater maximal hemoglobin decreases. These findings suggest that the combination of peginterferon α-2a plus ribavirin or with ribavirin and amantadine is effective in some HCV patients who relapse after treatment with interferon α-2b plus ribavirin.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Zeuzem S, Feinman SV, Rasenack J, et al.: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343:1666–1672, 2000
Reddy KR, Wright TL, Pockros PJ, et al.: Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 33:433–438, 2001
Lindsay KL, Trepo C, Heintges T, et al.: A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34:395–403, 2001
Heathcote EJ, Shiffman ML, Cooksley WG, et al.: Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 343:1673–1680, 2000
Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982, 2002
Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965, 2001
Davis GL, Esteban-Mur R, Rustgi V, et al.: Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 339:1493–1499, 1998
Cornberg M, Hinrichsen H, Teuber G, et al.: Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C. J Hepatol 37:843–847, 2002
Maes BD, van Pelt JF, Peeters JC, et al.: The effect of mycopheno- late mofetil on hepatitis B viral load in stable renal transplant recipients with chronic hepatitis B. Transplantation 72:1165–1166, 2001
Neyts J, Andrei G, De Clercq E: The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob Agents Chemother 42:216–222, 1998
Platz KP, Mueller AR, Willimski C, et al.: Indication for mycophenolate mofetil therapy in hepatitis C patients undergoing liver transplantation. Transplant Proc 30:2232–2233, 1998
Reines ED, Gross PA: Antiviral agents. Med Clin North Am 72:691–715, 1988
Brillanti S, Levantesi F, Masi L, et al.: Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 32:630–634, 2000
Mangia A, Minerva N, Annese M, et al.: A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. Hepatology 33:989–993, 2001
Tabone M, Laudi C, Delmastro B, et al.: Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients. J Hepatol 35:517–521, 2001
Caronia S, Bassendine MF, Barry R, et al.: Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study. The UK Amantadine Study Group. J Hepatol 35:512–516, 2001
Torre F, Giusto R, Grasso A, et al.: Clearance kinetics of hepatitis C virus under different antiviral therapies. J Med Virol 64:455–459, 2001
Helbling B, Stamenic I, Viani F, et al.: Interferon and amantadine in naïve chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. Hepatology 35:447–454, 2002
Baisini O, Gracielle Pigozzi M, Benini F, et al.: A randomised, open label, controlled trial on the effect of interferon plus amantadine compared with interferon alone for treatment of chronic hepatitis C. Hepatol Res 26:167–173, 2003
Nakamura H, Uyama H, Enomoto H, et al.: The combination therapy of interferon and amantadine hydrochloride for patients with chronic hepatitis C. Hepatogastroenterology 50:222–226, 2003
Bonkovsky HL, Stefancyk D, McNeal K, et al.: Comparative effects of different doses of ribavirin plus interferon α-2b for therapy of chronic hepatitis C. Results of a controlled, randomized trial. Dig Dis Sci 46:2051–2059, 2001
Berg T, Kronenberger B, Hinrichsen H, et al.: Triple therapy with amantadine in treatment-naïve patients with chronic hepatitis C: a placebo-controlled trial. Hepatology 37:1359–1367, 2003
Smith JP: Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 42:1681–1687, 1997
Torre F, Campo N, Giusto R, et al.: Antiviral activity of amantadine in elderly patients with chronic hepatitis C. Gerontology 47:330–333, 2001
Yagura M, Harada H: Treatment of chronic hepatitis C patients with amantadine. J Gastroenterol 36:759–763, 2001
Jubin R, Murray MG, Howe AY, et al.: Amantadine and rimantadine have no direct inhibitory effects against hepatitis C viral protease, helicase, ATPase, polymerase, and internal ribosomal entry site-mediated translation. J Infect Dis 18:331–334, 2000
Bacosi M, Russo F, D’innocenzo S, et al.: Amantadine and interferon in the combined treatment of hepatitis C virus in elderly patients. Hepatol Res 22:231–239, 2002
Teuber G, Berg T, Naumann U, et al.: Randomized, placebo-controlled, double-blind trial with interferon-alpha with and without amantadine sulphate in primary interferon-alpha nonresponders with chronic hepatitis C. J Viral Hepat 8:276–283, 2001
Gaeta GB, Stornaiuolo G, Stanzione M, et al.: Interferon-alpha plus amantadine in chronic hepatitis C resistant to interferon alone: a pilot randomized study. J Viral Hepat 8:284–286, 2001
DiMartino V, Boudjema H, Delacour T, et al.: Treatment of chronic hepatitis C with amantadine hydrochloride in patients who had not responded to previous treatment with interferon-alpha and/or ribavirin. Clin Infect Dis 32:830–831, 2001
Younossi ZM, Mullen KD, Zakko W, et al.: A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy. J Hepatol 34:128–133, 2001
Ullerich H, Avenhaus W, Poremba C, et al.: High-dose interferon alpha-2a with ribavirin and amantadine in naïve chronic hepatitis C patients—results of a randomized, prospective, pilot study. Aliment Pharmacol Ther 16:2107–2114, 2002
Zilly M, Lingenauber C, Desch S, et al.: Triple antiviral re-therapy for chronic hepatitis C with interferon-alpha, ribavirin, and amantadine in nonresponders to interferon-alpha and ribavirin. Eur J Med Res 7:149–154, 2002
Thuluvath PJ, Pande H, Maygers J: Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin. Dig Dis Sci 48:594–597, 2003
Piai G, Rocco P, Tartaglione MT, et al.: Triple (interferon, ribavirin, amantadine) versus double (interferon, ribavirin) re-therapy for interferon relapser genotype 1b HCV chronic active hepatitis patients. Hepatol Res 25:355–363, 2003
Adinolfi LE, Utili R, Tonziello A, et al.: Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial. Gut 52:701–705, 2003
Weegink CJ, Sentjens RE, Beld MG, et al.: Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction dose of 18 MU interferon-alpha in combination with ribavirin and amantadine: a two-arm randomized pilot study. J Viral Hepatol 10:174–182, 2003
Halloran PF: Molecular mechanisms of new immunosuppressants. Clin Transplant 10:118–123, 1996
Paterson DL, Singh N, Panebianco A, et al.: Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil. Transplantation 66:593–598, 1998
Firpi RJ, Nelson DR, Davis GL: Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. Liver Transpl 9:57–61, 2003
Shepherd J, Waugh N, Hewitson P: Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol Assess 4:1–67, 2000
Kjaergard LL, Krogsgaard K, Gluud C: Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ 323:1151–1155, 2001
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Herrine, S.K., Brown, R.S., Bernstein, D.E. et al. Peginterferon α-2a Combination Therapies in Chronic Hepatitis C Patients Who Relapsed After or Had a Viral Breakthrough on Therapy with Standard Interferon α-2b Plus Ribavirin: A Pilot Study of Efficacy and Safety. Dig Dis Sci 50, 719–726 (2005). https://doi.org/10.1007/s10620-005-2563-3
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10620-005-2563-3